Cargando…

Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline

The systemic therapy management of metastatic colorectal cancer (mCRC) has evolved from primarily cytotoxic chemotherapies to now include targeted agents given alone or in combination with chemotherapy, and immune checkpoint inhibitors. A better understanding of the pathogenesis and molecular driver...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Irene S., Aubin, Francine, Goodwin, Rachel, Loree, Jonathan M., Mather, Cheryl, Sheffield, Brandon S., Snow, Stephanie, Gill, Sharlene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310231/
https://www.ncbi.nlm.nih.gov/pubmed/35898967
http://dx.doi.org/10.1177/17588359221111705
_version_ 1784753344531660800
author Yu, Irene S.
Aubin, Francine
Goodwin, Rachel
Loree, Jonathan M.
Mather, Cheryl
Sheffield, Brandon S.
Snow, Stephanie
Gill, Sharlene
author_facet Yu, Irene S.
Aubin, Francine
Goodwin, Rachel
Loree, Jonathan M.
Mather, Cheryl
Sheffield, Brandon S.
Snow, Stephanie
Gill, Sharlene
author_sort Yu, Irene S.
collection PubMed
description The systemic therapy management of metastatic colorectal cancer (mCRC) has evolved from primarily cytotoxic chemotherapies to now include targeted agents given alone or in combination with chemotherapy, and immune checkpoint inhibitors. A better understanding of the pathogenesis and molecular drivers of colorectal cancer not only aided the development of novel targeted therapies but led to the discovery of tumor mutations which act as predictive biomarkers for therapeutic response. Mutational status of the KRAS gene became the first genomic biomarker to be established as part of standard of care molecular testing, where KRAS mutations within exons 2, 3, and 4 predict a lack of response to anti- epidermal growth factor receptor therapies. Since then, several other biomarkers have become relevant to inform mCRC treatment; however, there are no published Canadian guidelines which reflect the current standards for biomarker testing. This guideline was developed by a pan-Canadian advisory group to provide contemporary, evidence-based recommendations on the minimum acceptable standards for biomarker testing in mCRC, and to describe additional biomarkers for consideration.
format Online
Article
Text
id pubmed-9310231
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-93102312022-07-26 Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline Yu, Irene S. Aubin, Francine Goodwin, Rachel Loree, Jonathan M. Mather, Cheryl Sheffield, Brandon S. Snow, Stephanie Gill, Sharlene Ther Adv Med Oncol Review The systemic therapy management of metastatic colorectal cancer (mCRC) has evolved from primarily cytotoxic chemotherapies to now include targeted agents given alone or in combination with chemotherapy, and immune checkpoint inhibitors. A better understanding of the pathogenesis and molecular drivers of colorectal cancer not only aided the development of novel targeted therapies but led to the discovery of tumor mutations which act as predictive biomarkers for therapeutic response. Mutational status of the KRAS gene became the first genomic biomarker to be established as part of standard of care molecular testing, where KRAS mutations within exons 2, 3, and 4 predict a lack of response to anti- epidermal growth factor receptor therapies. Since then, several other biomarkers have become relevant to inform mCRC treatment; however, there are no published Canadian guidelines which reflect the current standards for biomarker testing. This guideline was developed by a pan-Canadian advisory group to provide contemporary, evidence-based recommendations on the minimum acceptable standards for biomarker testing in mCRC, and to describe additional biomarkers for consideration. SAGE Publications 2022-07-20 /pmc/articles/PMC9310231/ /pubmed/35898967 http://dx.doi.org/10.1177/17588359221111705 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Yu, Irene S.
Aubin, Francine
Goodwin, Rachel
Loree, Jonathan M.
Mather, Cheryl
Sheffield, Brandon S.
Snow, Stephanie
Gill, Sharlene
Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
title Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
title_full Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
title_fullStr Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
title_full_unstemmed Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
title_short Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
title_sort tumor biomarker testing for metastatic colorectal cancer: a canadian consensus practice guideline
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310231/
https://www.ncbi.nlm.nih.gov/pubmed/35898967
http://dx.doi.org/10.1177/17588359221111705
work_keys_str_mv AT yuirenes tumorbiomarkertestingformetastaticcolorectalcanceracanadianconsensuspracticeguideline
AT aubinfrancine tumorbiomarkertestingformetastaticcolorectalcanceracanadianconsensuspracticeguideline
AT goodwinrachel tumorbiomarkertestingformetastaticcolorectalcanceracanadianconsensuspracticeguideline
AT loreejonathanm tumorbiomarkertestingformetastaticcolorectalcanceracanadianconsensuspracticeguideline
AT mathercheryl tumorbiomarkertestingformetastaticcolorectalcanceracanadianconsensuspracticeguideline
AT sheffieldbrandons tumorbiomarkertestingformetastaticcolorectalcanceracanadianconsensuspracticeguideline
AT snowstephanie tumorbiomarkertestingformetastaticcolorectalcanceracanadianconsensuspracticeguideline
AT gillsharlene tumorbiomarkertestingformetastaticcolorectalcanceracanadianconsensuspracticeguideline